Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV

Exavir Therapeutics, a company dedicated to transforming the lives of patients living with or at risk for acquiring HIV and other viral infections, announced today the publication of preclinical data for XVIR-210, an investigational agent being developed as a long-acting antiviral for chronic HBV treatment, HIV treatment and prophylaxis, and HIV-HBV co-infection.